{"id":35,"date":"2024-08-29T22:50:11","date_gmt":"2024-08-29T22:50:11","guid":{"rendered":"http:\/\/stage.aftpharm.com\/my-en\/?page_id=35"},"modified":"2026-02-24T03:10:28","modified_gmt":"2026-02-24T03:10:28","slug":"about","status":"publish","type":"page","link":"https:\/\/www.aftpharm.com\/my-en\/about\/","title":{"rendered":"About us"},"content":{"rendered":"\n
\n
\n
\n
\n
What we do<\/h6>\n\n\n\n

Pharmaceuticals with a difference<\/h2>\n\n\n\n

With a guiding principle of working to improve your health, we deliver pharmaceuticals that make a real difference to people\u2019s health.<\/strong><\/h4>\n\n\n\n

Here at AFT Pharmaceuticals, our company vision is simple: to develop innovative products that help people. We do this by seeing opportunities that others may have missed, and by filling gaps in the market with innovative products that can provide positive health outcomes for those who need them.<\/p>\n\n\n\n

Our success is built on research and development. R&D is more than \u2018corporate speak\u2019 for us: it\u2019s at the heart of what we do in developing new products or improving existing ones. This has allowed us to successfully grow our business year after year, and crucially, to meet the health needs of people in Australasia and around the globe.<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/span>
\n
\n

“At AFT Pharmaceuticals, we remain committed to reinvest into R&D to help people across the world.”<\/p>\n\n\n\n

Hartley Atkinson, Founder and Managing Director<\/p>\n<\/blockquote>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\n
\n

Malaysia Team<\/h2>\n<\/div>\n<\/div>\n\n\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Lorraine Corr Poppleton <\/h2>\n
Head of Promoted Products of AFT PHARMACEUTICALS (S.E. Asia) SDN BHD and AFT HONG KONG<\/div>\n <\/div>\n <\/div>\n<\/div>\n<\/div>\n\n\n
\n
\n
\n

The Board<\/h2>\n\n\n\n

Our board members<\/h4>\n<\/div>\n\n\n\n
\n
\n
View all staff<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n
\n
\n \"About\n <\/div>\n
\n
\n

\n David Flacks <\/h2>\n
AFT Pharmaceuticals Chair<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Dr Hartley Atkinson <\/h2>\n
CEO, Managing Director<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Marree Atkinson <\/h2>\n
Chief of Staff, Executive Director<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Andrew Lane <\/h2>\n
Independent Director<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Dr Ted Witek <\/h2>\n
Independent Director<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Allison Yorston <\/h2>\n
Independent Director<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n<\/div>\n\n\n
\n
\n
View all staff<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n\n\n
\n
\n

Latest news<\/h2>\n\n\n\n

Stay informed with out latest advancements in healthcare and pharmaceutical innovation<\/h4>\n<\/div>\n\n\n\n
\n
\n
More news<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n
\n
\n
\n
\n \"\" <\/div>\n
\n
\n

November 20, 2025<\/p>\n

AFT delivers 10th consecutive first half revenue increase<\/h2>\n

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 3…<\/p>\n <\/div>\n Read More<\/a>\n <\/div>\n<\/div>\n

\n
\n \"\" <\/div>\n
\n
\n

September 25, 2025<\/p>\n

On track for $300m FY27 revenue; positive iron IV study result<\/h2>\n

– Sales tracking in line with $300 million FY27 revenue target\r\n– Clinical trial supports the potential patient benefits of novel iron IV development …<\/p>\n <\/div>\n Read More<\/a>\n <\/div>\n<\/div>\n

\n
\n \"\" <\/div>\n
\n
\n

April 24, 2024<\/p>\n

AFT, Massey Ventures, Gilles McIndoe to develop scar treatment<\/h2>\n

AFT collaborate with Massey Ventures and Gilles McIndoe to begin the development of a topical treatment for keloid and hypertrophic scarring….<\/p>\n <\/div>\n Read More<\/a>\n <\/div>\n<\/div>\n <\/div>\n <\/div>\n\n